UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer

Gynecologic oncology, 2017-02, Vol.144 (2), p.279-284

2017

Volltextzugriff (PDF)

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

Breast cancer research : BCR, 2017-08, Vol.19 (1), p.89-8, Article 89

2017

Volltextzugriff (PDF)

Prone Breast Intensity Modulated Radiation Therapy: 5-Year Results

International journal of radiation oncology, biology, physics, 2014-07, Vol.89 (4), p.899-906

2014

Volltextzugriff (PDF)

Finding Ovarian Cancer

JNCI : Journal of the National Cancer Institute, 2012-01, Vol.104 (2), p.82-83

2012

Volltextzugriff (PDF)

Oxaliplatin With Weekly Bolus Fluorouracil and Low-Dose Leucovorin as First-Line Therapy for Patients With Colorectal Cancer

Journal of clinical oncology, 2003-07, Vol.21 (14), p.2703-2707

2003

Volltextzugriff (PDF)

Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy

Journal of clinical oncology, 1999-08, Vol.17 (8), p.2553-2561

1999

Volltextzugriff (PDF)

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

Clinical cancer research, 2012-12, Vol.18 (24), p.6748-6757

2012

Volltextzugriff (PDF)

Abstract PS12-26: “Bridge” neoadjuvant endocrine therapy for early stage breast cancer patients during COVID-19 at an academic hospital in NYC: Lessons learned

Cancer research (Chicago, Ill.), 2021-02, Vol.81 (4_Supplement), p.PS12-26-PS12-26

2021

Volltextzugriff (PDF)

Abstract OT1-01-03: Impact of RANKL inhibition on tumor microenvironment of early-stage breast cancer, a pre-surgical trial

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.OT1-01-03-OT1-01-03

2020

Volltextzugriff (PDF)

Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e12633-e12633

2022

Volltextzugriff (PDF)

Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.TPS604-TPS604

2019

Volltextzugriff (PDF)

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

Breast cancer research : BCR, 2014-03, Vol.16 (2), p.R32-R32, Article R32

2014

Volltextzugriff (PDF)

Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic

The oncologist (Dayton, Ohio), 2022-03, Vol.27 (2), p.89-96

2022

Volltextzugriff (PDF)

Risk for SARS-CoV-2 infection in patients with breast cancer treated with chemotherapy, biologic therapy or active surveillance: Patient outcomes from multicenter institution in New York

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1513-1513

2021

Volltextzugriff (PDF)

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer

Breast cancer research and treatment, 2018-02, Vol.168 (1), p.57-67

2018

Volltextzugriff (PDF)

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

The New England journal of medicine, 1988-09, Vol.319 (12), p.745-752

1988

Volltextzugriff (PDF)

Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group

Journal of clinical oncology, 2004-01, Vol.22 (1), p.120-126

2004

Volltextzugriff (PDF)

Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer

Journal of clinical oncology, 1999-03, Vol.17 (3), p.880-886

1999

Volltextzugriff (PDF)

Cardiac dysfunction in the trastuzumab clinical experience

Journal of clinical oncology, 2002-03, Vol.20 (5), p.1156-1157

Speyer, James

2002

Volltextzugriff (PDF)

Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases

Journal of clinical oncology, 2014-10, Vol.32 (28), p.3204-3205

2014

Volltextzugriff (PDF)

Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS1124-TPS1124

2017

Volltextzugriff (PDF)

A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.5564-5564

2014

Volltextzugriff (PDF)

Concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer: A feasibility trial

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS1147-TPS1147

2014

Volltextzugriff (PDF)

FIVE-YEAR RESULTS OF ADJUVANT RADIOTHER

International journal of radiation oncology, biology, physics, 2014-05, Vol.89 (4), p.899-906

2014

Volltextzugriff (PDF)

Abstract P5-19-23: A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P5-P5-19-23

2015

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(101)

Publikationsform

Artikel
(115)

Sprache

Englisch
(115)

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Humans
(65)
Life Sciences & Biomedicine
(64)
Female
(50)
Oncology
(47)
Biological And Medical Sciences
(39)
Medical Sciences
(38)
Middle Aged
(38)
Adult
(33)
Aged
(32)
Pharmacology. Drug Treatments
(29)
Antineoplastic Agents
(24)
Chemotherapy
(21)
Male
(20)
Ovarian Neoplasms - Drug Therapy
(16)
Drug Administration Schedule
(13)
Drug Evaluation
(13)
Fluorouracil - Administration & Dosage
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(11)
Antineoplastic Agents - Administration & Dosage
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer

A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer

Prone Breast Intensity Modulated Radiation Therapy: 5-Year Results

Finding Ovarian Cancer

Oxaliplatin With Weekly Bolus Fluorouracil and Low-Dose Leucovorin as First-Line Therapy for Patients With Colorectal Cancer

Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

Abstract PS12-26: “Bridge” neoadjuvant endocrine therapy for early stage breast cancer patients during COVID-19 at an academic hospital in NYC: Lessons learned

Abstract OT1-01-03: Impact of RANKL inhibition on tumor microenvironment of early-stage breast cancer, a pre-surgical trial

Nivolumab with chemotherapy as neoadjuvant treatment for inflammatory breast cancer

Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer

Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer

Outcomes of Breast Cancer Patients Treated with Chemotherapy, Biologic Therapy, Endocrine Therapy, or Active Surveillance During the COVID-19 Pandemic

Risk for SARS-CoV-2 infection in patients with breast cancer treated with chemotherapy, biologic therapy or active surveillance: Patient outcomes from multicenter institution in New York

Serial immunological parameters in a phase II trial of exemestane and low-dose oral cyclophosphamide in advanced hormone receptor-positive breast cancer

Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer

Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group

Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer

Cardiac dysfunction in the trastuzumab clinical experience

Clinical trial evidence of the antitumor activity of topical imiquimod for breast cancer skin metastases

Phase II trial of pembrolizumab in combination with nab-paclitaxel in patients with metastatic HER2-negative breast cancer

A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer

Concurrent adjuvant systemic therapy and accelerated radiotherapy in triple-negative breast cancer: A feasibility trial

FIVE-YEAR RESULTS OF ADJUVANT RADIOTHER

Abstract P5-19-23: A phase I clinical trial of ganetespib (heat shock protein 90 inhibitor) in combination with paclitaxel and trastuzumab in human epidermal growth factor receptor-2 positive (HER2+) metastatic breast cancer

Aktive Filter

Suchergebnisse filtern